Crescent Biopharma announced that its independent Compensation Committee approved the grant of options to purchase an aggregate of 52,500 ordinary shares to two non-executive employees as equity inducement awards. The options were approved on July 22, 2026, and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4). The options carry a 10-year term and an exercise price of $15.83, the closing price of Crescent's ordinary shares on Nasdaq on July 22, 2026. Vesting occurs as to one-fourth of the shares on the first anniversary of the employee's start date, with the remainder vesting monthly over the following three years, subject to continuous service.
Crescent Biopharma, Inc.Grant of inducement options to new employees is a routine capital event with no clear directional signal for the stock.